Nippon India Mutual Fund

Nippon India Nifty Pharma ETF-Growth

Equity: Sectoral-Pharma - Growth (Open ended)Download Report
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: NIFTY Pharma Total Return IndexCheck Portfolio Overlap →
₹29.08+0.05%
20 Nov 2026

Tracking Difference

Annualised return gap between Nippon India Nifty Pharma ETF-Growth and its benchmark index over 1Y, 3Y, 5Y and 10Y periods, compared to the average of all funds tracking the same benchmark.
Name1 Y3 Y5 Y10 Y
Fund-0.30%-0.32%-0.27%-
Avg. of funds with same benchmark-0.30%-0.32%-0.27%-

Rolling Returns Analysis

Rolling annualized returns of Nippon India Nifty Pharma ETF-Growth across 1Y, 3Y and 5Y windows — average, best, worst returns and percentage of positive return periods.
Metric1 Yr Rolling Returns3 Yr Rolling Returns5 Yr Rolling Returns7 Yr Rolling Returns
Analysis period08 Jul, 2022 - 20 Nov, 202619 Jul, 2024 - 20 Nov, 202627 Jul, 2026 - 20 Nov, 2026-
Average returns17.01%20.48%13.86%-
Standard deviation21.23%2.93%0.84%-
Best returns64.12%
1 year ending on 11 Mar, 2024
26.24%
3 years ending on 27 May, 2026
16.11%
5 years ending on 19 Nov, 2026
-
Worst returns-14.86%
1 year ending on 26 Jul, 2022
12.68%
3 years ending on 19 Jul, 2024
12.23%
5 years ending on 23 Oct, 2026
-
Period with positive return72.87%100.00%100.00%-
Period with return > 5%65.93%100.00%100.00%-
Period with return > 10%58.98%100.00%100.00%-
Period with return > 15%47.13%97.42%11.11%-
Beat % Category37.78%32.70%64.20%-
Beat % Benchmark37.69%19.97%24.69%-

Trailing Returns

Point-to-point returns of Nippon India Nifty Pharma ETF-Growth vs category average for YTD, 1M, 6M, 1Y, 3Y, 5Y and 10Y periods — with category rank and total funds count.
0%
10%
20%
30%
40%
25.4%
21.7%
25.7%
YTD
10.8%
11.8%
10.8%
1 M
14.5%
11.9%
14.7%
6 M
25.6%
19.8%
25.9%
1 Y
22.0%
21.0%
48.5%
3 Y
16.6%
15.9%
16.9%
5 Y
14.8%
11.1%
10 Y
Fund
Equity: Sectoral-Pharma
NIFTY Pharma Total Return Index
NameYTD1 M6 M1 Y3 Y5 Y10 YSince Inception
Fund25.40%10.82%14.54%25.57%22.02%16.60%-13.80%
Equity: Sectoral-Pharma21.75%11.77%11.94%19.81%21.01%15.94%14.83%-
NIFTY Pharma Total Return Index25.68%10.85%14.69%25.88%48.53%16.91%11.08%-
Rank in category8257554--
Funds in category3034332919154-

Period Returns

Calendar-year, quarterly and monthly return history of Nippon India Nifty Pharma ETF-Growth. Toggle between bar chart and table view to analyse periodic performance trends.

Historical Performance

Track NAV movement and cumulative returns of Nippon India Nifty Pharma ETF-Growth across 1M, 6M, 1Y, 3Y, 5Y and since-inception periods. Compare SIP and lumpsum growth over time.

Compare performance with respect to
Add benchmark

Frequently Asked Questions

What are the 1-year returns of Nippon India Nifty Pharma ETF-Growth?
Nippon India Nifty Pharma ETF-Growth has delivered a 1-year return of 25.57% as of 19 Nov 2026. During the same period, its benchmark NIFTY Pharma Total Return Index returned 25.88%. The fund has underperformed its benchmark over this period.
What are the 3-year returns of Nippon India Nifty Pharma ETF-Growth?
Nippon India Nifty Pharma ETF-Growth has delivered a 3-year CAGR of 22.02% as of 19 Nov 2026. Its benchmark NIFTY Pharma Total Return Index returned 48.53% CAGR over the same period. CAGR (Compounded Annual Growth Rate) is the right way to evaluate multi-year ETF performance as it smooths out year-to-year volatility.
What are the 5-year returns of Nippon India Nifty Pharma ETF-Growth?
Nippon India Nifty Pharma ETF-Growth has delivered a 5-year CAGR of 16.60% as of 19 Nov 2026. Its benchmark NIFTY Pharma Total Return Index returned 16.91% CAGR over the same period. A 5-year track record is considered a more reliable indicator of fund quality than shorter-term performance, as it captures at least one full market cycle.
What are the returns of Nippon India Nifty Pharma ETF-Growth since inception?
Since its launch on 12 Jul 2021, Nippon India Nifty Pharma ETF-Growth has delivered a CAGR of 13.80%. Since-inception returns reflect the fund's full history and give the most complete picture of long-term performance.
How has Nippon India Nifty Pharma ETF-Growth performed vs its category over the long term?
Over the long term, Nippon India Nifty Pharma ETF-Growth has ranked 5 out of 19 funds in the Equity: Sectoral-Pharma category on a 3-year basis, and 4 out of 15 funds on a 5-year basis. Category rank is one of several factors to consider alongside risk metrics and rolling return consistency when evaluating a fund.
What is the Sharpe ratio of Nippon India Nifty Pharma ETF-Growth?
The Sharpe ratio of Nippon India Nifty Pharma ETF-Growth is 1.06 (as of 19 Nov 2026). The Sharpe ratio measures how much return the fund generates per unit of risk (volatility) taken. A Sharpe ratio above 1.0 is generally considered good — the higher the ratio, the better the risk-adjusted return.
What is the alpha of Nippon India Nifty Pharma ETF-Growth?
The 3Y alpha of Nippon India Nifty Pharma ETF-Growth is 1.14% (as of 19 Nov 2026). Alpha measures the excess return generated by the fund over and above its benchmark NIFTY Pharma Total Return Index, after adjusting for risk. A positive alpha means the fund manager has added value beyond what the market delivered. A negative alpha means the fund has underperformed its benchmark on a risk-adjusted basis.
What is the beta of Nippon India Nifty Pharma ETF-Growth?
The beta of Nippon India Nifty Pharma ETF-Growth is 0.93 (as of 19 Nov 2026). Beta measures how sensitive the fund is to market movements relative to its benchmark NIFTY Pharma Total Return Index. A beta of 1 means the fund moves in line with the market. A beta above 1 means it is more volatile than the market; below 1 means it is less volatile. Nippon India Nifty Pharma ETF-Growth's beta of 0.93 indicates it is more defensive than its benchmark.
What are the rolling returns of Nippon India Nifty Pharma ETF-Growth?
The average 1-year and 3-year rolling returns of Nippon India Nifty Pharma ETF-Growth is 17.01% and 20.48% respectively. Rolling returns show the fund's annualized return across every possible 1-year and 3-year investment window, making them a far more reliable measure of consistency than point-to-point returns, which depend heavily on the start and end date chosen.